Comparison of DNA sequencing and Roche Linear array® in human papillomavirus (HPV) genotyping

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3939-3941

  Giuliani, Laura ^a   Coletti, Anna ^a   Syrjänen, Kari ^b   Favalli, Cartesio ^a   Ciotti, Marco ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

HPV genotyping; Multiple infections; Sequencing

Indexed keywords

DNA;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA SEQUENCE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; VIRUS DETECTION; WART VIRUS;

CELLS, CULTURED; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; SEQUENCE ANALYSIS, DNA; SPECIES SPECIFICITY;

EID: 33750700447     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. De Viliers EM, Fauquet C, Broker TR, Bernard HU and zur Hausen H: Classification of papillomaviruses. Virology 324: 17-27, 2004.
2. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
3. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Minoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
4. Bosh FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV: International biological study on cervical cancer (IBSCC) study group. Prevalence of Human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87: 796-802, 1995.
5. Cuschieri KS, Whitley MJ and Cubie AH: Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 73: 65-70, 2004.
6. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G and McGoogan E: Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 57: 68-72, 2004.
7. Kleter B, van Doorn LJ, Schrauwen L, Molijin A, Sastrowijoto S, ter Schegget J, Lindeman J, ter harmsal B, Burger M and Quint W: Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37: 2508-2517, 1999.
8. Bauer HM, Greer CE and Manos M: Determination of genital human papillomavirus infection using consensus PCR. In: Diagnostic Molecular Pathology: A Practical Approach. Herrington CS and McGee JOD (eds.). Oxford University Press, pp. 132-152, 1992.
9. Gravit PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR and Apple RJ: Improved amplification of genital human papillomaviruses. J Clin Microbiol 38: 357-361, 2000.
10. Kajer SK, van de Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Sunton M, Bock JR, Poll PA and Meijer CJ: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325: 572-576, 2002.
11. Schiffman M, Bauer H, Hoover R, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ and Wacholder S: Epidemiologic evidence showing the HPV infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958-964, 1993.
12. van der Graaf Y, Molijna A, Doornewaard H, Quint W, van Doom LJ and van den Tweel J. Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 756: 158-164, 2002.